Natco Pharma Ltd

Natco Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Natco Pharma Ltd

₹ 902 -1.13%
16 Jun - close price
natcopharma.co.in BSE: 524816 NSE: NATCOPHARM
About

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1]
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]

Key Points

Business Segments
1) Export Formulation (44% in Q3 FY25 vs 73% in FY23): [1] [2] The company manufactures and markets finished dosage formulations in 50+ countries, including the US, Canada, Brazil, and Europe. Major US partners include Sun-Ranbaxy, Aceto-Rising, Alvogen, Teva, Mylan, Actavis, Lupin, etc. Its international business focuses on Para IV and first-to-file molecules, with plans to expand into emerging markets like MENA, LATAM, and Southeast Asia. [3] [4]

Website BSE NSE
  • Market Cap ₹ 16,162 Cr.
  • Current Price ₹ 902
  • High / Low ₹ 1,639 / 660
  • Stock P/E 8.73
  • Book Value ₹ 409
  • Dividend Yield 1.05 %
  • ROCE 33.1 %
  • ROE 28.6 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 32.0% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
514 806 351 413 781 1,048 930 625 965 1,237 1,293 408 1,157
552 426 281 346 454 545 488 387 512 474 502 378 596
Operating Profit -38 379 70 68 328 504 442 238 453 763 791 29 561
OPM % -7% 47% 20% 16% 42% 48% 48% 38% 47% 62% 61% 7% 48%
10 33 16 19 18 15 25 30 36 40 51 168 62
Interest 4 3 2 3 1 3 3 4 4 4 3 3 9
Depreciation 36 37 38 38 38 40 40 40 52 40 42 44 94
Profit before tax -67 373 46 45 306 475 424 224 432 758 797 150 521
Tax % -9% 17% 19% 17% 17% 15% 15% 14% 19% 16% 17% 17% 18%
-61 308 38 37 254 405 360 192 349 636 661 125 428
EPS in Rs -3.36 16.87 2.07 2.04 13.92 22.63 20.11 10.72 19.49 35.53 36.91 6.97 23.90
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
622 716 1,059 1,958 2,091 1,986 1,790 1,654 1,768 2,351 3,569 4,094
436 487 778 1,266 1,163 1,170 1,212 1,236 1,555 1,506 1,929 1,950
Operating Profit 187 229 281 692 928 816 578 418 213 845 1,640 2,144
OPM % 30% 32% 26% 35% 44% 41% 32% 25% 12% 36% 46% 52%
16 -2 13 13 39 130 124 101 95 86 102 321
Interest 34 30 22 18 15 19 21 11 13 9 14 20
Depreciation 27 42 50 54 66 80 98 115 138 151 172 220
Profit before tax 141 154 222 634 888 847 583 392 156 771 1,555 2,226
Tax % 22% 1% 20% 22% 21% 21% 19% 21% 11% 17% 16% 17%
110 153 176 495 698 667 474 310 139 637 1,307 1,850
EPS in Rs 6.66 9.20 10.13 28.39 37.84 36.48 26.06 16.97 7.62 34.90 72.95 103.31
Dividend Payout % 15% 11% 12% 24% 22% 17% 26% 31% 59% 16% 13% 6%
Compounded Sales Growth
10 Years: 19%
5 Years: 18%
3 Years: 32%
TTM: 15%
Compounded Profit Growth
10 Years: 28%
5 Years: 32%
3 Years: 160%
TTM: 41%
Stock Price CAGR
10 Years: 8%
5 Years: 8%
3 Years: 11%
1 Year: -25%
Return on Equity
10 Years: 18%
5 Years: 17%
3 Years: 24%
Last Year: 29%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 33 33 35 35 37 36 36 36 36 36 36 36
Reserves 700 846 1,302 1,665 3,088 3,527 3,833 4,055 4,155 4,666 5,556 7,298
237 309 110 221 173 384 314 256 400 161 366 275
206 207 396 427 438 408 463 405 387 525 596 661
Total Liabilities 1,176 1,395 1,843 2,347 3,736 4,356 4,647 4,752 4,978 5,388 6,554 8,270
529 573 706 829 1,015 1,215 1,574 2,006 2,174 2,234 2,287 2,517
CWIP 93 101 212 336 480 638 518 223 129 63 134 225
Investments 89 131 94 95 150 244 191 337 550 658 742 855
465 590 831 1,087 2,091 2,259 2,363 2,186 2,125 2,434 3,392 4,673
Total Assets 1,176 1,395 1,843 2,347 3,736 4,356 4,647 4,752 4,978 5,388 6,554 8,270

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
172 125 190 330 476 699 422 184 58 784 1,196 1,662
-131 -148 -248 -291 -1,131 -645 -165 -3 -92 -437 -960 -1,444
-41 23 151 -46 652 -52 -261 -183 36 -347 -237 -212
Net Cash Flow 0 -1 93 -6 -3 1 -4 -3 1 1 -1 6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 68 96 88 87 106 90 109 88 119 123 110 105
Inventory Days 392 424 501 215 400 547 482 562 476 424 379 395
Days Payable 240 247 385 160 231 217 215 102 96 126 116 138
Cash Conversion Cycle 220 274 205 142 275 420 376 548 499 422 373 362
Working Capital Days 78 106 119 114 252 285 374 353 348 238 190 200
ROCE % 19% 18% 18% 39% 34% 24% 14% 9% 3% 16% 29% 33%

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
48.80% 48.80% 48.82% 48.84% 49.76% 49.71% 49.71% 49.71% 49.71% 49.62% 49.62% 49.56%
11.65% 11.67% 11.73% 11.91% 11.03% 12.82% 13.72% 16.14% 17.45% 17.51% 17.94% 17.49%
15.30% 14.30% 14.93% 15.38% 15.15% 14.01% 11.26% 9.69% 7.86% 6.75% 5.59% 5.64%
24.25% 25.23% 24.53% 23.87% 24.08% 23.48% 25.32% 24.46% 24.99% 26.13% 26.88% 27.30%
No. of Shareholders 92,4491,21,3361,35,3971,53,6631,55,1811,63,7532,07,5712,28,4672,51,4853,02,9443,45,3324,05,222

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls